MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseaseshas closed a Series A financing round, lead by BVF Partners LP. Other investors included Merck KGaA, Darmstadt, Germany.
MoonLake Immunotherapeutics was established by an international team of immunology specialists to create next-level therapies for inflammatory skin and joint diseases. MoonLake in-licensed Tri-specific Nanobody® Sonelokimab with potential in the treatment of inflammatory diseases from Merck KGaA and Ablynx. MoonLake will accelerate the clinical development of Sonelokimab for the treatment of inflammatory diseases in dermatology and rheumatology.
Kellerhals Carrard acted as legal advisor to MoonLake Immunotherapeutics on this transaction, Kellerhals Carrard team comprised of Nicolas Mosimann (lead, pictured), Marco Sibold, Larissa Simeon and Sophie Holdt (all Corporate/VC) and Melanie Huber (Employment Law).
Merck KGaA, Darmstadt, has acquired a stake in MoonLake Immunotherapeutics and out-licensed its Tri-specific Nanobody®, Sonelokimab (M1095/ALX 0761), for the treatment of
inflammatory diseases in dermatology and rheumatology, to MoonLake Immunotherapeutics AG.
Walder Wyss acted as legal advisor to Merck KGaA, Darmstadt, on the equity component of this transaction. The team was led by André Kuhn (Managing Associate, Corporate/M&A, pictured left), Christian Lütolf (Managing Associate, Corporate/M&A), Maurus Winzap (Partner, Tax), Riccardo Brazerol (Associate, Corporate/M&A) and Gaurav Bhagwanani (Associate, Employment).